Quick Answer
ARS Pharmaceuticals, Inc. reported Total Revenue of $84.28 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $84.28M | -5.5% |
| 2024 | $89.15M | +297063.3% |
| 2023 | $30.0K | -97.7% |
| 2022 | $1.32M | -76.1% |
| 2021 | $5.51M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.50M | +1471.6% | +106.8% |
| June 30, 2025 | $15.72M | +3043.4% | +97.1% |
| March 31, 2025 | $7.97M | — | +285.5% |
| September 30, 2024 | $2.07M | — | +313.6% |
| June 30, 2024 | $500.0K | +4900.0% | — |
| March 31, 2024 | $0.00 | -100.0% | — |
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $10.0K | -97.8% | -50.0% |
- ARS Pharmaceuticals, Inc. showed a decrease of -5.5% in Total Revenue compared to the prior fiscal year.
- Over the 2021–2025 period, ARS Pharmaceuticals, Inc.’s total revenue has grown by 1430.7% (from $5.51 million to $84.28 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: